Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 262

Sort by

Sort Order Select

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Jean L. Koff, Kumudha Balakrishnan, Michael Churnetski, Michelle J. Lee, Anna Kurilovich, Svetlana Paponova, Alexander Nesmelov, Ksenia Zornikova, Pavel Zemskiy, Alexander Bagaev, Nikita Kotlov, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 5759.

https://doi.org/10.1182/blood-2024-209996

Published: 2024

Journal Articles

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim, Dai Chihara, Luis E. Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, Chijioke Nze, Swaminathan P Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, Ayushi Chauhan, Michael R. Green, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4511.1.

https://doi.org/10.1182/blood-2024-205196

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Hun Ju Lee, Gregory Ravizzini, Eslam Aboismail, Jenna Wixom, Jared Henderson, Luis E. Fayad, Sairah Ahmed, Ranjit Nair, Jason R. Westin, Swaminathan P Iyer, Chijioke Nze, Ajlan Al Zaki, Francisco Vega, Michael Wang, Christopher R. Flowers, Luis Malpica

Blood (2024) 144 (Supplement 1): 1674.3.

https://doi.org/10.1182/blood-2024-212005

Published: 2024

Journal Articles

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

David Fox, Katherine L Rosettie, Fadoua El Moustaid, Anthony Masaquel, Lourenia Cassoli, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2024-198451

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Journal Articles

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

Elizabeth Rodriguez, Nader Kim El-Mallawany, Sairah Ahmed, Branko Cuglievan, John Andrew Livingston, Christopher R. Flowers, Qian Xiao, Michael E. Roth, Michelle A.T. Hildebrandt

Blood (2024) 144 (Supplement 1): 6359.

https://doi.org/10.1182/blood-2024-208944

Published: 2024

Journal Articles

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Blood (2024) 144 (Supplement 1): 6420.

https://doi.org/10.1182/blood-2024-211482

Published: 2024

Journal Articles

Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma

Dai Chihara, Micheal J. Kane, Christopher R. Flowers, Brian P. Hobbs

Blood (2024) 144 (Supplement 1): 4462.

https://doi.org/10.1182/blood-2024-193578

Published: 2024

Journal Articles

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Michelle J. Lee, Kumudha Balakrishnan, Pavel Zemskiy, James D. Ayres, Timothy J. McDonnell, Neha Akkad, Kiril Kriukov, Arina Tkachuk, Ksenia Zornikova, Krystle Nomie, Aleksander Bagaev, Jean L. Koff, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 6209.

https://doi.org/10.1182/blood-2024-210739

Published: 2024

Journal Articles

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Mazie Tsang, Urshila Durani, Jonathan R Day, Melissa C. Larson, Matthew Holets, Kathleen J Yost, Jonathon B. Cohen, Jonathan W. Friedberg, Izidore S. Lossos, Peter Martin, Brad S. Kahl, Thomas M. Habermann, Loretta Nastoupil, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Carla Casulo, Matthew J. Maurer

Blood (2024) 144 (Supplement 1): 7598.

https://doi.org/10.1182/blood-2024-210968

Published: 2024

Journal Articles

Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2023

Zhiping Luo, Meng Li, Christopher R. Flowers, Dai Chihara

Blood (2024) 144 (Supplement 1): 7597.

https://doi.org/10.1182/blood-2024-208810

Published: 2024

Journal Articles

Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas

Anath Lionel, Karmila Murphy, Amy A. Ayers, Christopher R. Flowers, Keyur P. Patel, Courtney D. DiNardo, Francisco Vega, Dai Chihara

Blood (2024) 144 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2024-211432

Published: 2024

Journal Articles

Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Blood (2024) 144 (Supplement 1): 1679.

https://doi.org/10.1182/blood-2024-209213

Published: 2024

Journal Articles

Prospective Observational Cohort Study to Collect Granular Social Determinants of Health Data for Transplant and Cellular Therapy Candidates and Recipients

Warren B Fingrut, KaNoisha Codrington, Ligny Hunter, Ricky Garcia, Charles Martinez, Gabriela Rondon, Denái R. Milton, Christopher R. Flowers, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 3573.1.

https://doi.org/10.1182/blood-2024-202666

Published: 2024

Journal Articles

Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 1652.

https://doi.org/10.1182/blood-2024-201078

Published: 2024

Journal Articles

An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL

Ranjit Nair, Daniela E. Duenas, Jingjing Liu, Rishab Prakash, Chen Zhou, Ayse A Koksoy, Jie Xu, Salome A McAllen, Luis Malpica, Raja Luthra, Francisco Vega, Roberto N. Miranda, Jianhua Zhang, L. Jeffrey Medeiros, Cara L Haymaker, Christopher R. Flowers, Sattva S. Neelapu, Swami P. Iyer

Blood (2024) 144 (Supplement 1): 455.

https://doi.org/10.1182/blood-2024-211900

Published: 2024

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Swati Goel, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Tara Sadeghi, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 999.

https://doi.org/10.1182/blood-2024-211587

Published: 2024

Journal Articles

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Blood (2024) 144 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2024-194681

Published: 2024

NARROW

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2023

Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas

Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Prospective Observational Cohort Study to Collect Granular Social Determinants of Health Data for Transplant and Cellular Therapy Candidates and Recipients

Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only